By Emily Olsen | Published May 18, 2026
The landmark No Surprises Act (NSA), enacted in 2022 to shield American patients from the financial trauma of unexpected out-of-network medical bills, is facing a deepening crisis of confidence. A coalition of powerful advocacy groups, including the American Federation of State, County, and Municipal Employees (AFSCME), the ERISA Industry Committee, and the Purchaser Business Group on Health, has issued a formal call for the Trump administration to investigate "structural conflicts of interest" within the Independent Dispute Resolution (IDR) process.
At the heart of the controversy is a system that, while successful in protecting individual patients from immediate billing shocks, has morphed into a high-volume, profit-driven mechanism that critics argue is artificially inflating healthcare costs for employers and consumers nationwide.
The Genesis of the No Surprises Act
The No Surprises Act was conceived as a bipartisan legislative triumph. Before its implementation, patients frequently faced "surprise" bills when they received care from out-of-network providers at in-network facilities—a scenario common in emergency rooms, anesthesiology, and radiology.
The law established a federal IDR process: if an insurer and a provider cannot agree on a payment rate for a service, the dispute is submitted to a government-certified third-party arbiter. This arbiter selects either the insurer’s offer or the provider’s offer. The process was designed to be a "baseball-style" arbitration—meant to incentivize both parties to submit reasonable, market-based bids to avoid the arbiter’s choice. However, the system has proven far more volatile than lawmakers originally envisioned.
Chronology of a Regulatory Struggle
- January 2022: The No Surprises Act officially takes effect, barring most surprise out-of-network billing.
- 2023–2024: Mounting friction between providers and insurers leads to a flurry of lawsuits. Providers argue that federal guidance on calculating the "Qualified Payment Amount" (QPA) unfairly favors insurers, while insurers argue that providers are gaming the system by initiating thousands of frivolous disputes.
- Mid-2025: CMS data reveals a staggering surge in volume, with nearly 1.2 million disputes filed in the first half of the year alone, far exceeding initial government projections.
- May 2026: A broad coalition of labor, employer, and purchaser groups writes to the Trump administration, formally alleging that the IDR process has been captured by private equity interests and is driving up national health expenditures.
The Data: A System Under Strain
The sheer volume of cases is perhaps the most glaring indicator of systemic failure. According to data from the Centers for Medicare & Medicaid Services (CMS), the IDR process is being overwhelmed. With 1.2 million cases processed in just six months, the administrative burden alone threatens the viability of the program.
More concerning to the coalition of groups is the win-loss ratio and the subsequent pricing impact. Statistical analysis suggests that healthcare providers are winning a lopsided majority of disputes. When providers win, the resulting arbitration awards are often significantly higher than what a patient or insurer would have paid had the provider been in-network.
The advocacy groups argue that these "inflated" awards do not exist in a vacuum. Because insurance premiums are largely determined by the total cost of care, these high arbitration settlements are eventually passed down the line. As one policy analyst noted, "Every time a provider wins an outsized award through the IDR process, it effectively acts as a tax on every employee covered by that health plan, manifesting as higher deductibles and stagnating wages."
Structural Conflicts and the Private Equity Influence
The most damning allegations in the recent letter concern the integrity of the arbiters themselves. Under current federal regulations, the IDR entities—the third-party firms tasked with making these billion-dollar decisions—are not required to operate with the same transparency as judicial bodies.
Research cited by the Private Equity Stakeholder Project suggests that at least one major IDR entity is backed by a private equity firm that also maintains significant investments in medical provider groups. This creates a "closed-loop" incentive structure:
- A private equity firm invests in a medical practice.
- That practice initiates a high volume of IDR disputes against insurance plans.
- The IDR entity, which is also backed by the same private equity parent, may be incentivized to rule in favor of the provider, thereby increasing the revenue of the portfolio company.
This conflict of interest creates a perverse incentive for high-volume litigation. The groups argue that arbiters are effectively incentivized to keep the dispute volume high, as they receive fees for processing each case. This cycle transforms the arbitration process from a dispute-resolution mechanism into a profit center for the financial entities backing the system.
Implications: The Path Toward Reform
The coalition’s letter to the Trump administration outlines a series of concrete steps intended to restore the integrity of the IDR process. The proposed reforms include:
1. Mandatory Ownership Disclosure
Arbiters should be required to publicly disclose their ownership structures, financial backers, and any potential business relationships with providers or insurance entities. Transparency, the groups argue, is the first step in identifying conflicts of interest that might skew decision-making.
2. Decertification of Conflicted Entities
The federal government must adopt a more aggressive stance toward entities that demonstrate bias. The groups are calling for the immediate decertification of IDR entities found to have direct financial ties to parties involved in the disputes they are tasked to settle.
3. Eligibility Screening
To stem the tide of the 1.2 million cases clogging the system, the coalition suggests the implementation of strict eligibility screenings. By automatically weeding out ineligible or frivolous claims before they reach an arbiter, the government could significantly reduce the administrative backlog and decrease the incentive for providers to use arbitration as a standard billing tactic.
Official Responses and the Future of the NSA
The Department of Health and Human Services (HHS) and CMS have acknowledged the challenges inherent in the IDR process but have struggled to balance the interests of providers, who feel underpaid, and insurers, who feel gouged.
While the No Surprises Act has undeniably achieved its primary goal—removing the patient from the middle of billing disputes—the secondary effects on market pricing and the integrity of arbitration have become a major political headache.
As the Trump administration weighs these demands, the broader healthcare industry is watching closely. If the government fails to rein in the arbitration process, the risk is a permanent inflationary pressure on the U.S. healthcare system. Conversely, if reforms are too aggressive, they could push providers out of the market, potentially limiting access to care in rural or underserved areas.
"The No Surprises Act was intended to be a shield for the patient," said a spokesperson for the ERISA Industry Committee. "It was never intended to be a subsidy for private equity firms or a pipeline for inflated provider reimbursements. We are calling on the administration to return this law to its original purpose: ensuring fair, predictable, and reasonable costs for all participants in the healthcare market."
As of late May 2026, the administration has not yet released a formal response to the coalition’s letter, but sources indicate that the rapid escalation of IDR volume and the concerns over private equity influence have placed the issue firmly on the agenda for upcoming regulatory reviews. The coming months will be critical in determining whether the IDR process can be salvaged or if the No Surprises Act will require a fundamental legislative overhaul.
